1. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger- Gateau P et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008; 64(5): 492–498.
2.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine. 2012; 367(9): 795–804.
3.
Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345: e6231.
4.
Bourin M. The problems with the use of benzodiazepines in elderly patients. Encephale. 2010; 36(4): 340–347.
5.
Catindig JA, Venketasubramanian N, Ikram MK, Chen C: Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors. J Neurol Sci 2012; 321: 11–16.
6.
Chen PL, Lee WJ, Sun WZ, Oyang YJ, Fuh JL. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One. 2012; 7(11): e49113.
7.
Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH: Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 2010; 67: 114–121.
8.
Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther 2017; 9(1): 71.
9.
Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2011; 28(1): 7–20.
10.
Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12(1):14-17.
11.
Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O’Meara ES, Longstreth Jr WT et al.: Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66: 336–342.
12.
Fourrier A, Letenneur L, Dartigues J, Moore N, Bégaud B. Benzodiazepine use in an elderly community-dwelling population. Eur J Clin Pharmacol 2001; 57(5): 419–425.
13.
Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012; 66(10): 869–873.
14.
Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study BMJ 2016; 352: 90.
15.
Holm E, Fosbol E, Pedersen H, Jensen TB, Nielsen M, Weeke P et al. Benzodiazepine use in Denmark 1997–2008. Eur Geriatr Med 2012; 3(5): 299–303.
16.
Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case-Control Analysis. Drug Saf 2015; 38(10): 909–919.
17.
Islam Md M, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen P-A et al. Benzodiazepine Use and Risk of Dementia in the Elderly Population: A Systematic Review and Meta-Analysis. Neuroepidemiology 2016; 47: 181–191.
18.
Kuerbis A, Sacco P, Blazer DG, Moore AA. Substance abuse among older adults. Clin Geriatr Med 2014; 30(3): 629–654.
19.
Lagnaoui R., Bégaud B., Moore N., Chaslerie A., Fourrier A., Letenneur L. et al. Benzodiazepine use and risk of dementia: a nested case-control study. Journal of clinical epidemiology 2002; 55(3): 314–318.
20.
Lagnaoui R, Tournier M, Moride Y et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing 2009; 38(2): 226–228.
21.
Lee J, Jung SJ, Choi J-W, Shin A, Lee YJ. Use of sedative-hypnotics and the risk of Alzheimer’s dementia: A retrospective cohort study. PLoS ONE 2018; 13(9): e0204413.
22.
Linden M, Bär T, Helmchen H. Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004; 16: 461–480.
23.
Liu C-L, Peng L-N, Chen Y-T, Lin M-H, Liu L-K, Chen L-K.Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: a hospital-based study. Arch Gerontol Geriatr 2011; 55(1): 148–151.
24.
Lucchetta RC, da Mata BPM, Mastroianni PC. Associationbetween Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-Analysis. Pharmacotherapy 2018; 38(10): 1010–1020.
25.
Luchsinger JA, Tang MX, Siddiqui M et al. Alcohol intake and risk of dementia. J Am Geriatr Soc 2004; 52: 540–546.
26.
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; upad288: 1475–1483.
27.
Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708–714.
28.
Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Mental health-related drug utilization among older adults: prevalence, trends, and costs. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 2005; 13(10): 892–900.
29.
May PC, Robison PM. GYKI 52466 protects against non- NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci Lett 1993; 152(1–2): 169–172.
30.
Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc 2011; 59(3): 473–481.
31.
Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. Am J Psychiatry 2020; 177(6): 497–505.
32.
Pariente A, de Gage SB, Moore N, Bégaud B. The Benzodiazepine– Dementia Disorders Link: Current State of Knowledge. CNS Drugs 2016; 30(1): 1–7. Epub 2015/12/31. 10.1007/ s40263-015-0305-4.
33.
Pieszka M, Szczurek P, Ropka-Molik K, Oczkowicz M, Pieszka M. Rola resweratrolu w regulacji metabolizmu komórkowego. The role of resveratrol in the regulation of cell metabolism – a review. Postępy Higieny i Medycyny Doświadczalnej (Advances in Hygiene and Experimental Medicine) 2016; 70: 1117–1123.
34.
Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29: 125–132.
35.
Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. 2016.
36.
Richard E, Reitz C, Honig LH, Schupf N, Tang M X, Manly JJ et al. Late-life depression, mild cognitive impairment, and dementia. JAMA neurology 2013); 70(3): 374–382.
37.
Stella F, Radanovic M, Balthazar ML, Canineu PR, de Souza LC, Forlenza OV. Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry 2014; 27(3): 230–235.
38.
Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29: 639–658.
39.
Tseng LY, Huang ST, Peng LN, Chen LK, Hsiao FY. Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2020; 17(1): 156–164.
40.
Van Strien AM, Koek HL, van Marum RJ, Emmelot-Vonk MH. Psychotropic medications, including short acting benzodiazepines, strongly increase the frequency of falls in elderly. Maturitas 2013;74(4): 357–362.
41.
Wick JY, The History of Benzodiazepines. The Consultant Pharmacist 2013; 28: 538–548.
42.
Willems IA, Gorgels WJ, Oude Voshaar RC, Mulder J, Lucassen PL. Tolerance to benzodiazepines among long-term users in primary care. Fam Pract 2013; 30: 404–410.
43.
World Health Organization: Dementia: A Public Health Priority. Geneva, World Health Organization 2012.
44.
Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J GeriatrPsychiatry 2011; 19: 151–159.
45.
Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/ aggression. Am J Geriatr Psychiatry 2015; 23(2): 130–140.
46.
Zhong G, Wang Y, Zhang Y, Zhao Y. Association between Benzodiazepine Use and Dementia: A Meta-Analysis. PLoS One 2015; 10(5): e0127836.
